Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol

1. Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104–14. doi: 10.1016/j.jhep.2019.03.013 BertuccioP MalvezziM CarioliG HashimD BoffettaP El-SeragHB Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma J Hepatol 2019 71 104 14 10.1016/j.jhep.2019.03.013 Open DOISearch in Google Scholar

2. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 2021; 397: 428–44. doi: 10.1016/S0140-6736(21)00153-7 ValleJW KelleyRK NerviB OhDY ZhuAX Biliary tract cancer Lancet 2021 397 428 44 10.1016/S0140-6736(21)00153-7 Open DOISearch in Google Scholar

3. Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127–40. doi: 10.1016/j.annonc.2022.10.506 VogelA BridgewaterJ EdelineJ KelleyRK KlümpenHJ MalkaD ESMO Guidelines Committee Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2023 34 127 40 10.1016/j.annonc.2022.10.506 Open DOISearch in Google Scholar

4. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Biliary tract cancers. V 3. [online]. 2023. [cited 2024 Feb 18]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Biliary tract cancers. V 3. [online] 2023 [cited 2024 Feb 18]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf Search in Google Scholar

5. Cancer in Slovenia 2020. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2023. Cancer in Slovenia 2020 Ljubljana Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry 2023 Search in Google Scholar

6. Đokic M, Stupan U, Licen S, Trotovsek B. Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer − institution experience with literature review. Radiol Oncol 2021; 56: 208–15. doi: 10.2478/raon-2021-0048 ĐokicM StupanU LicenS TrotovsekB Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer − institution experience with literature review Radiol Oncol 2021 56 208 15 10.2478/raon-2021-0048 Open DOISearch in Google Scholar

7. Fostea RM, Fontana E, Torga G, Arkenau HT. Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma. Cancers 2020; 12: 2599. doi: 10.3390/cancers12092599 FosteaRM FontanaE TorgaG ArkenauHT Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma Cancers 2020 12 2599 10.3390/cancers12092599 Open DOISearch in Google Scholar

8. Mirallas O, López-Valbuena D, García-Illescas D, Fabregat-Franco C, Verdaguer H, Tabernero, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open 2022;7: 100503. doi: 10.1016/j.esmoop.2022.100503 MirallasO López-ValbuenaD García-IllescasD Fabregat-FrancoC VerdaguerH Tabernero Advances in the systemic treatment of therapeutic approaches in biliary tract cancer ESMO Open 2022 7 100503 10.1016/j.esmoop.2022.100503 Open DOISearch in Google Scholar

9. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273–81. doi: 10.1056/NEJMoa0908721 ValleJ WasanH PalmerDH CunninghamD AnthoneyA MaraveyasA ABC-02 Trial Investigators Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 2010 362 1273 81 10.1056/NEJMoa0908721 Open DOISearch in Google Scholar

10. Oh DY, He AR, Qin S, Chen T, Okusaka T, Arndt Vogel, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVID 0a2200015. doi: 10.1056/EVIDoa2200015 OhDY HeAR QinS ChenT OkusakaT ArndtVogel Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer NEJM Evid 2022 1 EVID 0a2200015. 10.1056/EVIDoa2200015 Open DOISearch in Google Scholar

11. Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis 2017; 2: 101–39. doi: 10.3233/TRD-170015 FerreiraCR GahlWA Disorders of metal metabolism Transl Sci Rare Dis 2017 2 101 39 10.3233/TRD-170015 Open DOISearch in Google Scholar

12. Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics 2021; 11: 8412–29. doi: 10.7150/thno.59092 MoralesM XueX Targeting iron metabolism in cancer therapy Theranostics 2021 11 8412 29 10.7150/thno.59092 Open DOISearch in Google Scholar

13. Stojsavljević, A, Vujotić L, Rovčanin B, Borković-Mitić S, Gavrović-Jankulović, Manojlović D. Assessment of trace metal alterations in the blood, cerebrospinal fluid and tissue samples of patients with malignant brain tumors. Sci Rep 2020; 10: 3816. doi: 10.1038/s41598-020-60774-0 StojsavljevićA VujotićL RovčaninB Borković-MitićS Gavrović-Jankulović ManojlovićD Assessment of trace metal alterations in the blood, cerebrospinal fluid and tissue samples of patients with malignant brain tumors Sci Rep 2020 10 3816 10.1038/s41598-020-60774-0 Open DOISearch in Google Scholar

14. Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. Cancers 2020; 12: 3594. doi: 10.3390/cancers12123594 LelièvreP SanceyL CollJL DeniaudA BusserB The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy Cancers 2020 12 3594 10.3390/cancers12123594 Open DOISearch in Google Scholar

15. Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427 ChenF HanB MengY HanY LiuB ZhangB Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer Aging 2021 13 20438 67 10.18632/aging.203427 Open DOISearch in Google Scholar

16. Wang B, Wang XP. Does ceruloplasmin defend against neurodegenerative diseases? Curr Neuropharmacol 2019; 17: 539–49. doi: 10.2174/1570159X16666180508113025 WangB WangXP Does ceruloplasmin defend against neurodegenerative diseases? Curr Neuropharmacol 2019 17 539 49 10.2174/1570159X16666180508113025 Open DOISearch in Google Scholar

17. Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics 2016; 8: 887–905. doi: 10.1039/c6mt00103c LinderMC Ceruloplasmin and other copper binding components of blood plasma and their functions: an update Metallomics 2016 8 887 905 10.1039/c6mt00103c Open DOISearch in Google Scholar

18. Mukae Y, Ito H, Miyata Y, Araki K, Matsuda T, Aibara N, et al. Ceruloplasmin levels in cancer tissues and urine are significant biomarkers of pathological features and outcome in bladder cancer. Anticancer Res 2021; 41: 3815–23. doi: 10.21873/anticanres.15174 MukaeY ItoH MiyataY ArakiK MatsudaT AibaraN Ceruloplasmin levels in cancer tissues and urine are significant biomarkers of pathological features and outcome in bladder cancer Anticancer Res 2021 41 3815 23 10.21873/anticanres.15174 Open DOISearch in Google Scholar

19. Sogabe M, Kojima S, Kaya T, Tomioka A, Kaji H, Sato T, et al. Sensitive new assay system for serum wisteria floribunda agglutinin-reactive ceruloplasmin that distinguishes ovarian clear cell carcinoma from endometrioma. Anal Chem 2022; 94: 2476–84. doi: 10.1021/acs.analchem.1c04302 SogabeM KojimaS KayaT TomiokaA KajiH SatoT Sensitive new assay system for serum wisteria floribunda agglutinin-reactive ceruloplasmin that distinguishes ovarian clear cell carcinoma from endometrioma Anal Chem 2022 94 2476 84 10.1021/acs.analchem.1c04302 Open DOISearch in Google Scholar

20. Michalczyk K, Cymbaluk-Płoska A. The role of zinc and copper in gynecological malignancies. Nutrients 2020; 12: 3732. doi: 10.3390/nu12123732 MichalczykK Cymbaluk-PłoskaA The role of zinc and copper in gynecological malignancies Nutrients 2020 12 3732 10.3390/nu12123732 Open DOISearch in Google Scholar

21. Woimant F, Djebrani-Oussedik N, Poujois A. New tools for Wilson’s disease diagnosis: exchangeablecopper fractio. Ann Transl Med 2019; 7(Suppl 2): S70. doi: 10.21037/atm.2019 WoimantF Djebrani-OussedikN PoujoisA New tools for Wilson’s disease diagnosis: exchangeablecopper fractio Ann Transl Med 2019 7 Suppl 2 S70 10.21037/atm.2019 Open DOISearch in Google Scholar

22. WHO Guidelines Review Committee, Nutrition and Food Safety (NFS). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations [Internet]. Geneva: World Health Organization 2020. [cited 2024 Jan 15]. Available at: https://www.who.int/publications/i/item/9789240000124. PMID: 33909381 WHO Guidelines Review Committee, Nutrition and Food Safety (NFS) WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations [Internet] Geneva World Health Organization 2020 [cited 2024 Jan 15]. Available at: https://www.who.int/publications/i/item/9789240000124. 33909381 Search in Google Scholar

23. Lossow K, Schwarz M, Kipp AP. Are trace element concentrations suitable biomarkers for the diagnosis of cancer? Redox Biol 2021; 42: 101900. doi: 10.1016/j.redox.2021.101900 LossowK SchwarzM KippAP Are trace element concentrations suitable biomarkers for the diagnosis of cancer? Redox Biol 2021 42 101900 10.1016/j.redox.2021.101900 Open DOISearch in Google Scholar

24. Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427 ChenF HanB MengY HanY LiuB ZhangB Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer Aging 2021 13 20438 67 10.18632/aging.203427 Open DOISearch in Google Scholar

25. Balter V, Nogueira da Costa A, Bondanese VP, Jaouen K, Lamboux A, et al. Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 2015; 112: 982–5. doi: 10.1073/pnas.1415151112 BalterV Nogueira da CostaA BondaneseVP JaouenK LambouxA Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients Proc Natl Acad Sci U S A 2015 112 982 5 10.1073/pnas.1415151112 Open DOISearch in Google Scholar

26. Hastuti AAMB, Costas-Rodríguez M, Matsunaga A, Ichinose T, Hagiwara S, Shimura M, et al. Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases. Sci Rep 2020; 10: 16389. doi: 10.1038/s41598-020-71764-7 HastutiAAMB Costas-RodríguezM MatsunagaA IchinoseT HagiwaraS ShimuraM Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases Sci Rep 2020 10 16389 10.1038/s41598-020-71764-7 Open DOISearch in Google Scholar

27. Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signaling to metalloplasia. Nat Rev Cancer 2022; 22: 102–13. doi: 10.1038/s41568-021-00417-2 GeEJ BushAI CasiniA CobinePA CrossJR DeNicolaGM Connecting copper and cancer: from transition metal signaling to metalloplasia Nat Rev Cancer 2022 22 102 13 10.1038/s41568-021-00417-2 Open DOISearch in Google Scholar

28. Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target. Cancer Biol Med 2020; 17: 612–25. doi: 10.20892/j.issn.2095-3941.2020.0106 WangJ ZhaoH XuZ ChengX Zinc dysregulation in cancers and its potential as a therapeutic target Cancer Biol Med 2020 17 612 25 10.20892/j.issn.2095-3941.2020.0106 Open DOISearch in Google Scholar

29. Krężel A, Maret W. The biological inorganic chemistry of zinc ions. Arch Biochem Biophys 2016; 611: 3–19. doi: 10.1016/j.abb.2016.04.010 KrężelA MaretW The biological inorganic chemistry of zinc ions Arch Biochem Biophys 2016 611 3 19 10.1016/j.abb.2016.04.010 Open DOISearch in Google Scholar

30. Infusino I, Valente C, Dolci A, Panteghini M. Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. Anal Bioanal Chem 2009; 397: 521–5. doi: 10.1007/s00216-009-3248-0 InfusinoI ValenteC DolciA PanteghiniM Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material Anal Bioanal Chem 2009 397 521 5 10.1007/s00216-009-3248-0 Open DOISearch in Google Scholar

31. Quarles CD, Macke M Jr, Michalke B, Zischka H, Karst U, Sullivan P, et al. LC-ICP-MS method for the determination of “extractable copper” in serum. Metallomics 2020; 12: 1348–55. doi: 10.1039/d0mt00132e QuarlesCD MackeMJr MichalkeB ZischkaH KarstU SullivanP LC-ICP-MS method for the determination of “extractable copper” in serum Metallomics 2020 12 1348 55 10.1039/d0mt00132e Open DOISearch in Google Scholar

32. Neselioglu S, Ergin M, Erel O. A new kinetic, automated assay to determine the ferroxidase activity of ceruloplasmin. Anal Sci 2017; 33: 1339–44. doi: 10.2116/analsci.33.1339 NeseliogluS ErginM ErelO A new kinetic, automated assay to determine the ferroxidase activity of ceruloplasmin Anal Sci 2017 33 1339 44 10.2116/analsci.33.1339 Open DOISearch in Google Scholar

33. Solovyev N, Ala A, Schilsky M, Mills C, Willis, K, Harrington C F. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma-mass spectrometry. Anal. Chim Acta 2020; 1098: 27–36. doi: 10.1016/j.aca.2019.11.033 SolovyevN AlaA SchilskyM MillsC WillisK HarringtonC F Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma-mass spectrometry Anal. Chim Acta 2020 1098 27 36 10.1016/j.aca.2019.11.033 Open DOISearch in Google Scholar

34. Bernevic B, El-Khatib AH, Jakubowski N, Weller MG. Online immunocapture ICP-MS for the determination of the metalloprotein ceruloplasmin in human serum. BMC Res Notes 2018; 11: doi:10.1186/s13104-018-3324-7 BernevicB El-KhatibAH JakubowskiN WellerMG Online immunocapture ICP-MS for the determination of the metalloprotein ceruloplasmin in human serum BMC Res Notes 2018 11 10.1186/s13104-018-3324-7 Open DOISearch in Google Scholar

35. Marković K, Milačič R, Vidmar J, Marković S, Uršič K, Nikšić Žakelj M, et al. Monolithic chromatography on conjoint liquid chromatography columns for speciation of platinum-based chemotherapeutics in serum of cancer patients. J Trace Elem Med Biol 2020; 57: 28–39. doi: 10.1016/j.jtemb.2019.09.011 MarkovićK MilačičR VidmarJ MarkovićS UršičK Nikšić ŽakeljM Monolithic chromatography on conjoint liquid chromatography columns for speciation of platinum-based chemotherapeutics in serum of cancer patients J Trace Elem Med Biol 2020 57 28 39 10.1016/j.jtemb.2019.09.011 Open DOISearch in Google Scholar

36. Marković K, Milačič R, Marković S, Kladnik J, Turel I, Ščančar J. Binding kinetics of ruthenium pyrithione chemotherapeutic candidates to human serum proteins studied by HPLC-ICP-MS. Molecules 2020; 25: 1512–3. doi: cules25071512 MarkovićK MilačičR MarkovićS KladnikJ TurelI ŠčančarJ Binding kinetics of ruthenium pyrithione chemotherapeutic candidates to human serum proteins studied by HPLC-ICP-MS Molecules 2020 25 1512 3 doi: cules25071512 Search in Google Scholar

37. Martinčič A, Čemažar M, Serša G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141–8, doi: 10.1016/j.talanta.2013.05.016 MartinčičA ČemažarM SeršaG KovačV MilačičR ŠčančarJ A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection Talanta 2013 116 141 8 10.1016/j.talanta.2013.05.016 Open DOISearch in Google Scholar

38. Martinčič A, Milačič R, Vidmar J, Turel I, Keppler BK, Ščančar J. New method for the speciation of Ru-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. J Chromatogr A 2014; 1371: 168–76. doi: 10.1016/j.chroma.2014.10.054 MartinčičA MilačičR VidmarJ TurelI KepplerBK ŠčančarJ New method for the speciation of Ru-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks J Chromatogr A 2014 1371 168 76 10.1016/j.chroma.2014.10.054 Open DOISearch in Google Scholar

39. Marković K, Cemazar M, Sersa G, Milačič R, Ščančar J. Speciation of copper in human serum using conjoint liquid chromatography on short-bed monolithic disks with UV and post column ID-ICP-MS detection. J Anal At Spectrom 2022; 37: 1675–86. doi: 10.1039/D2JA00161F MarkovićK CemazarM SersaG MilačičR ŠčančarJ Speciation of copper in human serum using conjoint liquid chromatography on short-bed monolithic disks with UV and post column ID-ICP-MS detection J Anal At Spectrom 2022 37 1675 86 10.1039/D2JA00161F Open DOISearch in Google Scholar

40. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62:132–7. doi: 10.1016/j.ejca.2016.03.081 SchwartzLH LitièreS de VriesE FordR GwytherS MandrekarS RECIST 1.1-Update and clarification: from the RECIST committee Eur J Cancer 2016 62 132 7 10.1016/j.ejca.2016.03.081 Open DOISearch in Google Scholar

41. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143–e52. doi: 10.1016/S1470-2045(17)30074-8. Erratum in: Lancet Oncol 2019; 20: e242. SeymourL BogaertsJ PerroneA FordR SchwartzLH MandrekarS RECIST working group iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Lancet Oncol 2017 18 e143 e52 10.1016/S1470-2045(17)30074-8 Erratum in: Lancet Oncol 2019; 20: e242. Open DOISearch in Google Scholar

42. National Cancer Institute (NCI). NCI common terminology criteria for adverse events (CTCAE). Version 5.0.2021. [cited 2024 Feb 18]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf National Cancer Institute (NCI) NCI common terminology criteria for adverse events (CTCAE). Version 5.0.2021 [cited 2024 Feb 18]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf Search in Google Scholar